Mon, May 10, 2010
Sun, May 9, 2010
Sat, May 8, 2010
Fri, May 7, 2010
Thu, May 6, 2010
Mon, January 11, 2010
Sat, January 9, 2010
Fri, January 8, 2010
Thu, January 7, 2010
Wed, January 6, 2010
Tue, January 5, 2010
Mon, January 4, 2010
[ Mon, Jan 04th 2010 ] - Market Wire
Cordani Becomes CIGNA CEO
Thu, December 31, 2009
[ Thu, Dec 31st 2009 ] - Market Wire
Quit the Board
Wed, December 30, 2009
Tue, December 29, 2009
Mon, December 28, 2009
Thu, December 24, 2009
Wed, December 23, 2009
Tue, December 22, 2009
Mon, December 21, 2009
Fri, December 18, 2009

AMAG Pharmaceuticals, Inc. to Present at the 28th Annual J.P. Morgan Healthcare Conference


//health-fitness.news-articles.net/content/2010/ .. 8th-annual-j-p-morgan-healthcare-conference.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


LEXINGTON, Mass.--([ BUSINESS WIRE ])--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Brian J.G. Pereira, MD, President and CEO, will present an overview of the Company and provide an update on the commercial launch of Feraheme® (ferumoxytol) Injection at the 28th Annual J.P. Morgan Healthcare Conference on January 11, 2010 at 11:00 a.m. P.T.

A live audio webcast of the presentation and the breakout session will be accessible through the Investors section of the Company's website at [ www.amagpharma.com ]. Following the conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website until February 11, 2010.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. AMAG received approval from the U.S. Food and Drug Administration to market Feraheme® (ferumoxytol) Injection for the treatment of iron deficiency anemia in adult chronic kidney disease patients on June 30, 2009. For additional company and product information, please visit [ www.amagpharma.com ].

Feraheme® is a registered trademark of AMAG Pharmaceuticals, Inc.


Publication Contributing Sources